Jyong Biotech Ltd.(MENS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
MENS Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Jyong Biotech Ltd. (MENS), a Healthcare sector company. MENS is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (FY 2025), Jyong Biotech Ltd. reports net income of $-4.7M, free cash flow of $-3.0M. Top institutional holders of MENS by reported 13-F value include BlackRock,, GEODE CAPITAL MANAGEMENT,, UBS Group AG, based on the most recent SEC filings. MENS trades on the Nasdaq exchange and files with the SEC under CIK 1954488. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MENS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Jyong Biotech Ltd. directly from SEC EDGAR.
Net Income
FY 2025
$-4.7M
Free Cash Flow
FY 2025
$-3.0M
AI Insight: MENS Financial Trends
Insufficient data: no quarterly financials available for trend analysis.
• No quarterly financial data provided for Jyong Biotech Ltd.
⚠ Obtain quarterly or annual financial statements to assess profitability, cash generation, and balance sheet health.
AI Insight: MENS Ratio Trends
Insufficient data: no financial ratios provided to assess Jyong Biotech's operational or profitability trends.
⚠ No ratio metrics available—unable to evaluate margin health, return on capital, or cash generation.
Get alerted when MENS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Jyong Biotech Ltd. including:
Top Institutional Holders of MENS
BlackRock, Inc.
$556.3K258,760 shGEODE CAPITAL MANAGEMENT, LLC
$138.1K64,232 shUBS Group AG
$80.3K37,363 shMILLENNIUM MANAGEMENT LLC
$31.4K14,590 shVanguard Personalized Indexing Management, LLC
$29.9K13,927 shChina Universal Asset Management Co., Ltd.
$28.3K13,173 shTower Research Capital LLC (TRC)
$25.2K11,703 shMORGAN STANLEY
$13.5K6,301 shBARCLAYS PLC
$11.2K5,189 shMirae Asset Global Investments Co., Ltd.
$8.3K3,872 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $556.3K | 258,760 |
| GEODE CAPITAL MANAGEMENT, LLC | $138.1K | 64,232 |
| UBS Group AG | $80.3K | 37,363 |
| MILLENNIUM MANAGEMENT LLC | $31.4K | 14,590 |
| Vanguard Personalized Indexing Management, LLC | $29.9K | 13,927 |
| China Universal Asset Management Co., Ltd. | $28.3K | 13,173 |
| Tower Research Capital LLC (TRC) | $25.2K | 11,703 |
| MORGAN STANLEY | $13.5K | 6,301 |
| BARCLAYS PLC | $11.2K | 5,189 |
| Mirae Asset Global Investments Co., Ltd. | $8.3K | 3,872 |
More Healthcare Companies
View all Healthcare →Put MENS on your watchlist
Track score changes the day Jyong Biotech Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MENS a good stock to buy?
13F Pro's AI-powered analysis of Jyong Biotech Ltd. (MENS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MENS are available on the MENS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own MENS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MENS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Jyong Biotech Ltd.'s investment landscape.